Liver Cancer Trial, Recruiting NCT05994859 Sponsor: Second Affiliated Hospital of Guangzhou Medical University Condition: Liver Cancer
Back to Liver Cancer

Liver Cancer Trial, Recruiting

NCT05994859
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have been diagnosed with hepatocellular carcinoma (liver cancer), confirmed either by a tissue sample or by clinical assessment
  • People who have not received any previous treatment for their liver cancer
  • People who have at least one measurable liver tumour that can be tracked during the trial
  • People whose liver cancer may be able to be surgically removed, where the tumour(s) are contained within one side of the liver, with or without limited spread into nearby blood vessels on the same side
  • People whose cancer is suitable for a type of internal radiation treatment called SIRT, as assessed by the trial team
  • People whose liver is functioning at a healthy level (Child-Pugh Class A) or who do not have liver scarring (cirrhosis)
  • People who are generally active and able to carry out daily activities, with only minor limitations (ECOG performance score of 0 or 1)
  • People with active hepatitis B, provided antiviral treatment has been used to reduce the hepatitis B virus to a very low level in the blood
  • People with hepatitis C, provided they have completed treatment for hepatitis C before joining
  • People whose blood test results show that their organs and bone marrow are functioning adequately, meeting specific blood count and chemistry thresholds (confirm with trial site for exact values)
  • People with a life expectancy of at least 6 months

Who may not be able to join:

  • People whose tumour involves the main portal vein, both branches of the portal vein, or the large vein running through the body (vena cava)
  • People whose tumour has spread beyond one lobe (section) of the liver
  • People who have tumours spread across both lobes of the liver
  • People whose cancer has spread outside the liver to other parts of the body
  • People with serious liver complications such as fluid build-up in the abdomen, bleeding from veins in the oesophagus or stomach, or confusion caused by liver failure
  • People with significant heart or kidney problems
  • People who test positive for both hepatitis B surface antigen and hepatitis C antibodies at the same time
  • People who have had a different type of cancer in the past, other than liver cancer
  • People with an infection that is not under control
  • People with a history of HIV
  • People who have previously had an organ or cell transplant
  • People who have a tendency to bleed or have bleeding disorders

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: +86-20-34156205

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Second Affiliated Hospital of Guangzhou Medical University
Registry
ClinicalTrials.gov
Start date
10 August 2023
Est. completion
9 August 2026

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Success rate of conversion to resection

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov